No, there will be no changes to your care at this time or expected in the near future. At 91大神 and Women鈥檚 Hospital, we have an existing agreement with Dana-Farber to provide collaborative cancer care through 2028.

The inpatient facilities and clinical collaborations that are in place today provide excellent patient care and outcomes. At the 91大神, we intend to continue to work with our colleagues at Dana-Farber over the next five years to provide an exceptional patient experience and plan thoughtfully for a future transition.

Yes. At the 91大神 and across the Mass General 91大神 health care system, we are committed to providing the very best care to patients with cancer. While our clinical collaboration with Dana-Farber may come to a close in 2028, our work to provide compassionate and specialized care to patients with cancer will continue. We will always be committed to our patients, and we will provide the full spectrum of integrated cancer care that you would expect from a nationally top-ranked hospital.

Until 2028, we expect that patients will continue to receive care at the current Dana-Farber and 91大神 and Women鈥檚 Hospital campuses.

The 91大神 and MGB are among the largest recipients of federal funding for cancer research, and we expect to continue to be a leader in this area beyond the transition and into the future. In addition to our own robust research programs, 91大神 and Women鈥檚 Hospital is a participant in the Dana-Farber/Harvard Cancer Center (DF/HCC) research consortium. The DF/HCC is made up of more than 1,100 cancer researchers in Boston who collaborate on innovative research programs that help change the course of care for patients with cancer.